| Risk of pancreatic cancer in families with Lynch syndrome F Kastrinos, B Mukherjee, N Tayob, F Wang, J Sparr, VM Raymond, ... Jama 302 (16), 1790-1795, 2009 | 657 | 2009 |
| Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome E Stoffel, B Mukherjee, VM Raymond, N Tayob, F Kastrinos, J Sparr, ... Gastroenterology 137 (5), 1621-1627, 2009 | 454 | 2009 |
| Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study MLK Han, Y Zhou, S Murray, N Tayob, I Noth, VN Lama, BB Moore, ... The Lancet Respiratory Medicine 2 (7), 548-556, 2014 | 407 | 2014 |
| Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis PK Naik, PD Bozyk, JK Bentley, AP Popova, CM Birch, CA Wilke, CD Fry, ... American Journal of Physiology-Lung Cellular and Molecular Physiology 303 …, 2012 | 298 | 2012 |
| Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy MLK Han, N Tayob, S Murray, MT Dransfield, G Washko, PD Scanlon, ... American journal of respiratory and critical care medicine 189 (12), 1503-1508, 2014 | 229 | 2014 |
| Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema SL Schmidt, AM Nambiar, N Tayob, B Sundaram, MK Han, BH Gross, ... European Respiratory Journal 38 (1), 176-183, 2011 | 174 | 2011 |
| Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer P Tarantino, Q Jin, N Tayob, RM Jeselsohn, SJ Schnitt, J Vincuilla, ... JAMA oncology 8 (8), 1177-1183, 2022 | 173 | 2022 |
| International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma AG Singal, Y Hoshida, DJ Pinato, J Marrero, JC Nault, V Paradis, N Tayob, ... Gastroenterology 160 (7), 2572-2584, 2021 | 149 | 2021 |
| Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ... Journal of Clinical Oncology 39 (21), 2375-2385, 2021 | 134 | 2021 |
| The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States N Tayob, F Kanwal, A Alsarraj, R Hernaez, HB El-Serag Clinical Gastroenterology and Hepatology 21 (2), 415-423. e4, 2023 | 132 | 2023 |
| Predicting pulmonary fibrosis disease course from past trends in pulmonary function SL Schmidt, N Tayob, MK Han, C Zappala, D Kervitsky, S Murray, ... Chest 145 (3), 579-585, 2014 | 130 | 2014 |
| Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma JF Liu, N Xiong, SM Campos, AA Wright, C Krasner, S Schumer, ... Journal of Clinical Oncology 39 (14), 1531-1539, 2021 | 124 | 2021 |
| GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis AG Singal, N Tayob, A Mehta, JA Marrero, H El‐Serag, Q Jin, ... Hepatology 75 (3), 541-549, 2022 | 121 | 2022 |
| Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? ND Parikh, N Tayob, AG Singal Journal of hepatology 78 (1), 207-216, 2023 | 107 | 2023 |
| Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline ML Salisbury, M Xia, Y Zhou, S Murray, N Tayob, KK Brown, AU Wells, ... Chest 149 (2), 491-498, 2016 | 105 | 2016 |
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial SM Tolaney, P Tarantino, N Graham, N Tayob, L Parè, G Villacampa, ... The Lancet Oncology 24 (3), 273-285, 2023 | 104 | 2023 |
| Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm N Tayob, ASF Lok, KA Do, Z Feng Clinical gastroenterology and hepatology 14 (3), 469-475. e2, 2016 | 98 | 2016 |
| Barriers to surveillance for hepatocellular carcinoma in a multicenter cohort ND Parikh, N Tayob, T Al-Jarrah, J Kramer, J Melcher, D Smith, ... JAMA network open 5 (7), e2223504-e2223504, 2022 | 63 | 2022 |
| A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer PA Konstantinopoulos, AABA da Costa, D Gulhan, EK Lee, SC Cheng, ... Nature communications 12 (1), 5574, 2021 | 52 | 2021 |
| Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa P Moodley, NS Shah, N Tayob, C Connolly, N Zetola, N Gandhi, ... PloS one 6 (5), e17513, 2011 | 50 | 2011 |